CNPR Market Analysis 5 — Questions and Answers
Question 1: What is the significance of 'Wholesale Acquisition Cost' (WAC) in pharmaceutical market analysis?
- The price a consumer pays at the pharmacy
- The published list price at which manufacturers sell to wholesalers, used as a benchmark (Correct answer)
- The actual net price after all rebates and discounts
- The price set by the FDA for Medicare coverage
Correct answer: The published list price at which manufacturers sell to wholesalers, used as a benchmark
WAC is the manufacturer's published list price to wholesalers, serving as a reference starting point before rebates and discounts are applied.
Question 2: A pharmaceutical company observes that its drug has high awareness among physicians but low prescribing rates. The most likely explanation is:
- The drug lacks FDA approval
- There are market access, formulary, or clinical barriers preventing prescribing (Correct answer)
- The sales force is too large for the market
- The drug's brand name is too similar to a competitor
Correct answer: There are market access, formulary, or clinical barriers preventing prescribing
High awareness combined with low prescribing suggests barriers between intent and action, such as formulary restrictions, cost, or clinical hesitancy.
Question 3: In analyzing pharmaceutical market trends, 'genericization' refers to:
- The process of launching a drug in new international markets
- The market impact when branded drugs face generic competition after patent expiry (Correct answer)
- Prescribing drugs off-label for unapproved uses
- The consolidation of multiple branded drugs into one generic formulation
Correct answer: The market impact when branded drugs face generic competition after patent expiry
Genericization describes the market shift when generic versions enter after patent expiration, typically causing rapid brand revenue and share erosion.
Question 4: Which business concept helps explain why a pharmaceutical company might continue selling a loss-leading product in a therapeutic category?
- Portfolio strategy — maintaining market presence to protect other profitable products in the category (Correct answer)
- Regulatory compliance requirement from the FDA
- Pressure from KOLs to maintain availability
- Product liability protection strategy
Correct answer: Portfolio strategy — maintaining market presence to protect other profitable products in the category
Portfolio strategy justifies maintaining a loss-leading product when its presence protects or enhances the commercial performance of more profitable products in the same area.
Question 5: What does a 'market development' strategy involve in pharmaceutical marketing?
- Gaining share from competitors within an existing patient population
- Expanding the treated patient population by identifying undiagnosed or undertreated patients (Correct answer)
- Reducing the price to attract cost-sensitive prescribers
- Launching the drug in international markets only
Correct answer: Expanding the treated patient population by identifying undiagnosed or undertreated patients
Market development focuses on growing the overall market size by identifying and bringing untreated or undiagnosed patients into therapy.
Question 6: When evaluating a sales territory's performance, which comparison provides the most meaningful context for a rep's results?
- Comparing current month sales to the previous month in isolation
- Comparing territory performance to national average and peer territories over the same period (Correct answer)
- Reviewing the number of physician calls made
- Tracking sample distribution rates only
Correct answer: Comparing territory performance to national average and peer territories over the same period
Benchmarking against national averages and peer territories in the same time period controls for market-wide factors and reveals true relative performance.
Question 7: In pharmaceutical market analysis, a 'lagging indicator' would be best exemplified by:
- Early physician adoption rates from a product launch survey
- Total annual prescription volume reported at year end (Correct answer)
- Current formulary coverage decisions by major payers
- Physician awareness levels measured during pre-launch research
Correct answer: Total annual prescription volume reported at year end
Total annual prescription volume is a lagging indicator because it reflects outcomes of past marketing and sales activities, not current or future trends.
CNPR Market Analysis 5
What is the significance of 'Wholesale Acquisition Cost' (WAC) in pharmaceutical market analysis?